About Genesis Therapeutics
Genesis Therapeutics is a Healthcare company based in San Francisco (United States) founded in 2019 by Ben Sklaroff, James Schaeffer, and Evan Feinberg. Computational platform for AI-driven small molecule drug discovery is developed. It operates in the Healthcare and Technology sectors. Genesis Therapeutics has raised $304.02 million across 5 funding rounds from investors including Fidelity Investments, BlackRock and T. Rowe Price. Its chief executive, as recorded, is Evan Feinberg. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its legal entity is GENESIS THERAPEUTICS, INC. Its competitors include Relay Therapeutics, Atomwise and Unnatural Products; 3 of its 3 listed competitors have raised funding.
Company details
Genesis Therapeutics was founded in 2019 in San Francisco, United States, within the biotechnology sector. A computational platform is utilized for small molecule drug discovery, incorporating artificial intelligence. Neural networks and biophysical simulations are integrated with a scalable computing infrastructure to support drug design and development. Operations center on enhancing efficiency in pharmaceutical innovation through these methods.
- Headquarters San Francisco, United States
- Founders Ben Sklaroff, James Schaeffer, Evan Feinberg
- SectorsHealthcareTechnology
- Email••••••••
- Website genesistherapeutics.ai
- Social LinkedIn
- Legal Name Genesis Therapeutics, Inc.
- Total Equity Funding$304.02M (USD)
in 5 rounds
- InvestorsFidelity Investments
& 15 more
Funding Insights of Genesis Therapeutics
Genesis Therapeutics has successfully raised a total of $304.02M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $304.02M
- Total Rounds 5
- First Round $4.1M
(Nov 2019)
- Investors Count 16
All 5 funding rounds of Genesis Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2024 | Series B | – | NVentures | – | |
| Aug 2023 | $224.03M | Series B | – | a16z | |
| Jun 2022 | $23.89M | Series A | – | – | – |
| Dec 2020 | $52M | Series A | – | Rock Springs Capital | |
| Nov 2019 | $4.1M | Seed | – | a16z |
16 investors in total: 14 institutional and 2 angel.
Investors in Genesis Therapeutics
Genesis Therapeutics has secured backing from 16 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Fidelity Investments, BlackRock and T. Rowe Price.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital arm of Nvidia | nventures.ai | Santa Clara, United States | ||
Venture capital investments in technology sectors are handled by Andreessen Horowitz. | a16z.com | |||
Venture capital firm focused on AI-driven companies | radical.vc | Toronto, Canada | ||
Early-stage venture capital firm investing in AI, healthcare, and tech sectors. | menlovc.com | |||
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
Investments in technology startups are made by Felicis Ventures. | felicis.com | Menlo Park, United States | ||
Tech & Life Science focused VC firm investing in the US | jazzvp.com | San Francisco, United States | ||
Venture capital investments are made in American technological innovation. | 2018 | harpoon.vc | ||
Seed-stage funding is provided to innovative founder teams. | uluventures.com | Palo Alto, United States | ||
Early-stage deep tech companies are funded by Propagator Ventures. | propagator.vc | Oslo, Norway |
Investor details for Genesis Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Genesis Therapeutics
29 people are tracked at Genesis Therapeutics (15 in leadership, 1 in board & advisors, 13 in team).
| Name | Role | Group |
|---|---|---|
Ben Sklaroff | Co-Founder & CTO | Leadership |
James Schaeffer | Co-Founder | Leadership |
Evan Feinberg | Co-Founder & CEO | Leadership |
Will McCarthy | COO | Leadership |
Stephen Dann | Senior VP Of Biology | Leadership |
Christina Adams | Associate Director, Biology | Leadership |
Wang Xu | Vp, Finance And Controller | Leadership |
Marissa (Smith) Baker | Director Of Biology | Leadership |
Matthew MacKenzie | Associate Director, Fp&a | Leadership |
Louie Naumovski | CMO | Leadership |
Deirdre Costello | Associate Director, Structural Biology | Leadership |
Irene Hyo | Head Of People, Sr. Director | Leadership |
Martin Rowbottom | Executive Director, Medicinal Chemistry | Leadership |
Géza Ambrus-Aikelin | Head Of Immunology & Inflammation | Leadership |
Lisa Nguyen | Associate Director Of Biology | Leadership |
Leonard Bell | Chairman | Board & advisors |
Joel Springer | Senior Manager, Recruiting Operations And Strategy | Team |
Jennifer Bodily | Talent Operations And Talent Acquisition | Team |
Luis Landgrave | Procurement Manager | Team |
Bing Han | Accounting Manager | Team |
9 more people are available in the full profile.
Complete people profiles for Genesis Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Genesis Therapeutics
3 dated milestones of Genesis Therapeutics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Genesis Therapeutics is founded.
- Funding First funding round of $4.1M.
- Funding Latest funding round, Series B,.
Competitors of Genesis Therapeutics
Genesis Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Relay Therapeutics, Atomwise and Unnatural Products.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| relaytx.com | 2016 | Cambridge, United States | $520M | 261 | Drug discovery platform is developed to study protein motion. | |
| atomwise.com | 2012 | San Francisco, United States | $218.64M | 70 | AI-driven platform for structure-based drug discovery is provided. | |
| unnaturalproducts.com | 2016 | Santa Cruz, United States | $38M | 22 | Peptides are engineered via computational biology for undruggable targets. |
Detailed competitors of Genesis Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Genesis Therapeutics
Websites that share an audience with Genesis Therapeutics (genesistherapeutics.ai).
Websites whose visitors overlap most with Genesis Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
genengnews.com | genengnews.com | 100% | #281,744 | – | |
| arxiv.org | 66% | 24.2M | #2,532 | View details | |
| overleaf.com | 66% | 36.7M | #1,656 | View details |
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Genesis Therapeutics (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Genesis Therapeutics
Complete news archive for Genesis Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genesis Therapeutics
Genesis Therapeutics was founded in 2019.
Genesis Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Evan Feinberg is the CEO of Genesis Therapeutics, as recorded in our data. They have also founded this company.
Genesis Therapeutics is a funded company, having raised a total of $304.02M across 5 funding rounds to date. The company's 1st funding round was a Seed of $4.1M, raised on Nov 2019.
Genesis Therapeutics was founded in 2019 in San Francisco, United States, within the biotechnology sector. A computational platform is utilized for small molecule drug discovery, incorporating artificial intelligence. Neural networks and biophysical simulations are integrated with a scalable computing infrastructure to support drug design and development. Operations center on enhancing efficiency in pharmaceutical innovation through these methods.
Genesis Therapeutics's top competitors include Atomwise, Unnatural Products and Relay Therapeutics.
Genesis Therapeutics has 16 investors. Key investors include Fidelity Investments, BlackRock, T. Rowe Price, NVentures, and Andreessen Horowitz.
Genesis Therapeutics operates through Genesis Therapeutics, Inc..